Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial

Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) has anti-cancer effects and adverse events across a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Main Authors: Miyata, Yasuyoshi, Araki, Kyohei, Ohba, Kojiro, Mastuo, Tomhiro, Nakamura, Yuichiro, Yuno, Tsutomu, Mukai, Yuta, Otsubo, Asato, Mitsunari, Kensuke, Mochizuki, Yasushi, Sakai, Hideki
Formato: Artigo
Idioma:Inglês
Publicado: D.A. Spandidos 2020
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403815/
https://ncbi.nlm.nih.gov/pubmed/32765876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2099
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares